Alvaro Aa Avezum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3867343/publications.pdf

Version: 2024-02-01

244 papers

72,248 citations

98 h-index 904 248 g-index

264 all docs

264 docs citations

times ranked

264

65986 citing authors

#	Article	IF	CITATIONS
1	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 462-473.	1.4	8
2	Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. European Heart Journal, 2022, 43, 202-209.	1.0	14
3	Differences and agreement between two portable hand-held spirometers across diverse community-based populations in the Prospective Urban Rural Epidemiology (PURE) study. PLOS Global Public Health, 2022, 2, e0000141.	0.5	2
4	Variations in risks from smoking between high-income, middle-income, and low-income countries: an analysis of data from 179â€^000 participants from 63 countries. The Lancet Global Health, 2022, 10, e216-e226.	2.9	16
5	Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis. EClinicalMedicine, 2022, 44, 101284.	3.2	21
6	Medications for blood pressure, blood glucose, lipids, and anti-thrombotic medications: relationship with cardiovascular disease and death in adults from 21 high-, middle-, and low-income countries with an elevated body mass index. European Journal of Preventive Cardiology, 2022, 29, 1817-1826.	0.8	2
7	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC Open, 2022, 4, 568-576.	0.7	4
8	Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy. European Heart Journal, 2022, 43, 2841-2851.	1.0	30
9	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	1.4	6
10	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE $\hat{a} \in \text{``Coalition V')}$: A double-blind, multicentre, randomised, controlled trial. The Lancet Regional Health Americas, 2022, 11, 100243.	1.5	11
11	Variations in the association of height with mortality, cardiovascular disease and cancer in low-, middle- and high-income countries. International Journal of Epidemiology, 2022, 51, 1304-1316.	0.9	3
12	The World Heart Observatory: Harnessing the Power of Data for Cardiovascular Health. Global Heart, 2022, 17, .	0.9	2
13	Association of Sitting Time With Mortality and Cardiovascular Events in High-Income, Middle-Income, and Low-Income Countries. JAMA Cardiology, 2022, 7, 796.	3.0	30
14	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. JAMA Cardiology, 2021, 6, 21-29.	3.0	33
15	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	1.0	17
16	Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals. Cardiovascular Research, 2021, 117, 1523-1531.	1.8	33
17	Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Case–Control Study. American Journal of Hypertension, 2021, 34, 414-425.	1.0	6
18	Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level. Heart, 2021, 107, 282-289.	1.2	25

#	Article	IF	Citations
19	Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study. Neuroepidemiology, 2021, 55, 206-215.	1.1	2
20	Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study. BMJ, The, 2021, 372, m4948.	3.0	53
21	Impact of social isolation on mortality and morbidity in 20 high-income, middle-income and low-income countries in five continents. BMJ Global Health, 2021, 6, e004124.	2.0	48
22	Associations of unprocessed and processed meat intake with mortality and cardiovascular disease in 21 countries [Prospective Urban Rural Epidemiology (PURE) Study]: a prospective cohort study. American Journal of Clinical Nutrition, 2021, 114, 1049-1058.	2.2	46
23	Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arquivos Brasileiros De Cardiologia, 2021, 116, 516-658.	0.3	340
24	Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. New England Journal of Medicine, 2021, 384, 1312-1322.	13.9	124
25	Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study. Sleep Medicine, 2021, 80, 265-272.	0.8	11
26	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. JAMA Internal Medicine, 2021, 181, 631.	2.6	68
27	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007.	1.0	18
28	Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. New England Journal of Medicine, 2021, 384, 2081-2091.	13.9	321
29	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet, The, 2021, 397, 2253-2263.	6.3	366
30	Timing and Length of Nocturnal Sleep and Daytime Napping and Associations With Obesity Types in High-, Middle-, and Low-Income Countries. JAMA Network Open, 2021, 4, e2113775.	2.8	24
31	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. BMJ, The, 2021, 374, n1554.	3.0	136
32	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	1.2	31
33	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial. American Heart Journal, 2021, 238, 1-11.	1.2	19
34	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke, 2021, 52, 2494-2501.	1.0	10
35	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. JAMA Cardiology, 2021, 6, 1042.	3.0	35
36	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1133-1146.	6.3	87

#	Article	IF	CITATIONS
37	Posicionamento sobre Hipertensão Arterial e Espiritualidade – 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 599-613.	0.3	O
38	The Need for Brazil to Focus on CVD. Global Heart, 2020, 11, 439.	0.9	0
39	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology, 2020, 27, 296-307.	0.8	28
40	Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet, The, 2020, 395, 785-794.	6.3	428
41	Modifiable risk factors, cardiovascular disease, and mortality in 155â€^722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet, The, 2020, 395, 795-808.	6.3	935
42	Real-world' observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	0.7	18
43	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 106-114.	5.5	77
44	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. Diabetes Care, 2020, 43, 3094-3101.	4.3	32
45	Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Global Health, 2020, 5, e002640.	2.0	41
46	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New England Journal of Medicine, 2020, 383, 2041-2052.	13.9	903
47	Associations of outdoor fine particulate air pollution and cardiovascular disease in 157â€^436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet Planetary Health, The, 2020, 4, e235-e245.	5.1	106
48	White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries. Diabetes Care, 2020, 43, 2643-2650.	4.3	55
49	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke, 2020, 51, 2901-2909.	1.0	15
50	Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147 812 individuals from 21 countries. BMJ Open Diabetes Research and Care, 2020, 8, e000826.	1.2	57
51	The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. American Heart Journal, 2020, 225, 69-77.	1.2	43
52	Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. JAMA Psychiatry, 2020, 77, 1052.	6.0	116
53	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. Europace, 2020, 22, 870-877.	0.7	13
54	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation, 2020, 141, 1841-1854.	1.6	96

#	Article	IF	Citations
55	Long-term exposure to outdoor and household air pollution and blood pressure in the Prospective Urban and Rural Epidemiological (PURE) study. Environmental Pollution, 2020, 262, 114197.	3.7	47
56	Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. American Journal of Clinical Nutrition, 2020, 111, 795-803.	2.2	71
57	Perspectives in Chagas Disease Treatment. Global Heart, 2020, 10, 189.	0.9	4
58	Os Percentis e Pontos de Corte da Circunferência Abdominal para Obesidade em uma Ampla Amostra de Estudantes de 6 a 10 Anos de Idade do Estado de São Paulo, Brasil. Arquivos Brasileiros De Cardiologia, 2020, 114, 530-537.	0.3	6
59	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke, 2019, 14, 270-281.	2.9	11
60	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	1.0	2,687
61	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 2019, 157, 682-691.e2.	0.6	299
62	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, 157, 403-412.e5.	0.6	108
63	Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 2019, 381, 1411-1421.	13.9	542
64	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation, 2019, 140, 1451-1459.	1.6	36
65	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	6.3	1,625
66	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	6.3	394
67	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation, 2019, 140, 529-537.	1.6	81
68	Health Effects of Household Solid Fuel Use: Findings from 11 Countries within the Prospective Urban and Rural Epidemiology Study. Environmental Health Perspectives, 2019, 127, 57003.	2.8	117
69	Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. The Lancet Global Health, 2019, 7, e613-e623.	2.9	122
70	Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. The Lancet Global Health, 2019, 7, e748-e760.	2.9	340
71	Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. BMJ: British Medical Journal, 2019, 364, 1772.	2.4	85
72	Effects of blood pressure and lipid lowering on cognition. Neurology, 2019, 92, e1435-e1446.	1.5	54

#	Article	IF	CITATIONS
73	Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries. Journal of Hypertension, 2019, 37, 1813-1821.	0.3	56
74	Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy. Journal of the American Society of Echocardiography, 2019, 32, 286-295.e3.	1.2	21
75	Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology. Global Heart, 2019, 14, 3.	0.9	13
76	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 787-891.	0.3	102
77	Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. The Lancet Global Health, 2018, 6, e292-e301.	2.9	73
78	Epicardial adipose tissue and metabolic syndrome. Medicine (United States), 2018, 97, e0387.	0.4	2
79	Metabolic syndrome and risk of stroke. Medicine (United States), 2018, 97, e9862.	0.4	9
80	Statins in adult patients with HIV. Medicine (United States), 2018, 97, e0116.	0.4	4
81	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 75-81.	1.4	9
82	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart, 2018, 104, 1292-1299.	1.2	14
83	Independent predictors of effective blood pressure control in patients with hypertension on drug treatment in Brazil. Journal of Clinical Hypertension, 2018, 20, 125-132.	1.0	8
84	Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. Heart, 2018, 104, 581-587.	1.2	49
85	Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet, The, 2018, 392, 2288-2297.	6.3	295
86	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet, The, 2018, 391, 2019-2027.	6.3	96
87	Effects of Lipid‣owering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPEâ€3 Trial. Journal of the American Heart Association, 2018, 7, .	1.6	1
88	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. Open Heart, 2018, 5, e000800.	0.9	9
89	Epicardial adipose tissue and carotid artery disease. Medicine (United States), 2018, 97, e0273.	0.4	2
90	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes and Endocrinology,the, 2018, 6, 798-808.	5.5	116

#	Article	IF	Citations
91	Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet, The, 2018, 392, 496-506.	6.3	243
92	High-density lipoprotein-cholesterol functionality and metabolic syndrome. Medicine (United States), 2018, 97, e11094.	0.4	3
93	Challenges and Opportunities to Scale Up Cardiovascular Disease Secondary Prevention in Latin America and the Caribbean. Global Heart, 2018, 13, 83.	0.9	6
94	Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes (<scp>REWIND</scp>) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism, 2018, 20, 42-49.	2.2	160
95	Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries. BMJ Open, 2017, 7, e013817.	0.8	44
96	Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	0.8	133
97	The effect of physical activity on mortality and cardiovascular disease in 130â€^000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet, The, 2017, 390, 2643-2654.	6.3	838
98	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	13.9	1,745
99	Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet, The, 2017, 390, 2050-2062.	6.3	841
100	Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet, The, 2017, 390, 2037-2049.	6.3	446
101	Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. Lancet Diabetes and Endocrinology,the, 2017, 5, 774-787.	5.5	198
102	Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health, The, 2017, 2, e411-e419.	4.7	134
103	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. International Journal of Cardiology, 2017, 245, 271-276.	0.8	22
104	Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries. BMJ Global Health, 2017, 2, e000443.	2.0	15
105	Conversion after off-pump coronary artery bypass grafting: the CORONARY trial experience. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw361.	0.6	6
106	Secondary CV Prevention in South America in a Community Setting: The PURE Study. Global Heart, 2017, 12, 305.	0.9	35
107	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	13.9	526
108	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	13.9	641

#	Article	IF	Citations
109	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	13.9	299
110	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. International Journal of Cardiology, 2016, 218, 291-297.	0.8	8
111	Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet, The, 2016, 388, 465-475.	6.3	381
112	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. American Heart Journal, 2016, 178, 145-150.	1.2	52
113	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet, The, 2016, 388, 1161-1169.	6.3	216
114	Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 535-546.	2.9	191
115	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. Journal of the American Heart Association, 2016, 5, .	1.6	18
116	Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet Global Health, 2016, 4, e695-e703.	2.9	287
117	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, The, 2016, 388, 761-775.	6.3	1,414
118	Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. New England Journal of Medicine, 2016, 375, 2359-2368.	13.9	326
119	Lipoproteinâ€Associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2016, 5, .	1.6	44
120	Benznidazole for Chronic Chagas' Cardiomyopathy. New England Journal of Medicine, 2016, 374, 188-190.	13.9	15
121	Association of Urinary Sodium Excretion With Blood Pressure and Cardiovascular Clinical Events in 17,033 Latin Americans. American Journal of Hypertension, 2016, 29, 796-805.	1.0	26
122	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. Diabetes Care, 2016, 39, 780-787.	4.3	138
123	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age and Ageing, 2016, 45, 77-83.	0.7	91
124	Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35–70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study. Injury Prevention, 2016, 22, 92-98.	1.2	28
125	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet, The, 2016, 387, 127-135.	6.3	187
126	Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet, The, 2016, 387, 61-69.	6.3	272

#	Article	IF	Citations
127	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318.	0.8	24
128	Cardiovascular Disease Burden: Evolving Knowledge of Risk Factors in Myocardial Infarction and Stroke through Population-Based Research and Perspectives in Global Prevention. Frontiers in Cardiovascular Medicine, 2015, 2, 32.	1.1	66
129	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. European Heart Journal, 2015, 36, ehv447.	1.0	35
130	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. European Heart Journal, 2015, 36, 281-288.	1.0	253
131	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. Circulation, 2015, 132, 624-632.	1.6	203
132	Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet, The, 2015, 386, 266-273.	6.3	1,295
133	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. New England Journal of Medicine, 2015, 372, 1389-1398.	13.9	536
134	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. American Journal of Medicine, 2015, 128, 766-775.	0.6	81
135	Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 386, 1243-1253.	6.3	268
136	Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. Lancet, The, 2015, 386, 1945-1954.	6.3	163
137	Psychosocial factors and obesity in 17 high-, middle- and low-income countries: the Prospective Urban Rural Epidemiologic study. International Journal of Obesity, 2015, 39, 1217-1223.	1.6	29
138	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	0.7	951
139	Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. New England Journal of Medicine, 2015, 373, 1295-1306.	13.9	807
140	Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Global Heart, 2015, 10, 99.	0.9	82
141	Stroke in Latin America: Burden of Disease and Opportunities for Prevention. Global Heart, 2015, 10, 323.	0.9	55
142	The environmental profile of a community's health: a cross-sectional study on tobacco marketing in 16 countries. Bulletin of the World Health Organization, 2015, 93, 851-861G.	1.5	29
143	The association between ownership of common household devices and obesity and diabetes in high, middle and low income countries. Cmaj, 2014, 186, 258-266.	0.9	62
144	Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. Journal of Hypertension, 2014, 32, 1005-1015.	0.3	174

#	Article	IF	Citations
145	Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. American Heart Journal, 2014, 167, 315-321.e1.	1.2	66
146	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine, 2014, 370, 1702-1711.	13.9	467
147	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. Circulation, 2014, 129, 1568-1576.	1.6	324
148	Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events. New England Journal of Medicine, 2014, 371, 612-623.	13.9	725
149	Association of Urinary Sodium and Potassium Excretion with Blood Pressure. New England Journal of Medicine, 2014, 371, 601-611.	13.9	687
150	Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries. New England Journal of Medicine, 2014, 371, 818-827.	13.9	679
151	Amiodarone, Anticoagulation, andÂClinicalÂEvents in Patients WithÂAtrialÂFibrillation. Journal of the American College of Cardiology, 2014, 64, 1541-1550.	1.2	84
152	A Novel Method to Evaluate the Community Built Environment Using Photographs – Environmental Profile of a Community Health (EPOCH) Photo Neighbourhood Evaluation Tool. PLoS ONE, 2014, 9, e110042.	1.1	18
153	Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA - Journal of the American Medical Association, 2013, 310, 959.	3.8	1,422
154	Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. American Heart Journal, 2013, 166, 636-646.e4.	1.2	113
155	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, 128, 237-243.	1.6	195
156	Management of diabetes mellitus and associated cardiovascular risk factors in Brazil – the Brazilian study on the practice of diabetes care. Diabetology and Metabolic Syndrome, 2013, 5, 46.	1.2	4
157	Response to Letters Regarding Article, "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial― Circulation, 2013, 127, e506.	1.6	2
158	Risk factors for pre, intra, and postoperative hospital mortality in patients undergoing aortic surgery. Brazilian Journal of Cardiovascular Surgery, 2013, 28, 10-21.	0.2	7
159	Cardiovascular prevention in coronary heart disease patients: guidelines implementation in clinical practice. Brazilian Journal of Cardiovascular Surgery, 2013, 28, 238-247.	0.2	5
160	Acute Coronary Syndrome Behavior: Results of a Brazilian Registry. Arquivos Brasileiros De Cardiologia, 2013, 100, 502-10.	0.3	28
161	Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention. Circulation, 2012, 126, 2705-2712.	1.6	151
162	Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients. Circulation, 2012, 126, 278-286.	1.6	52

#	Article	IF	CITATIONS
163	Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. European Journal of Preventive Cardiology, 2012, 19, 755-764.	0.8	74
164	Environmental Profile of a Community's Health (EPOCH): An Ecometric Assessment of Measures of the Community Environment Based on Individual Perception. PLoS ONE, 2012, 7, e44410.	1.1	23
165	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. Circulation, 2012, 126, 343-348.	1.6	494
166	Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 806-817.	13.9	2,207
167	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2268-2276.	13.9	547
168	Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery. Annals of Internal Medicine, 2011, 154, 523.	2.0	557
169	Design and rationale of the Radial Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. American Heart Journal, 2011, 161, 254-260.e4.	1.2	46
170	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
171	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, The, 2011, 377, 1409-1420.	6.3	1,759
172	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet, The, 2011, 378, 1231-1243.	6.3	803
173	Comparação entre troponina I cardÃaca e CK-MB massa em sÃndrome coronariana aguda sem supra de ST. Arquivos Brasileiros De Cardiologia, 2011, 96, 179-187.	0.3	11
174	Pulmonary Function In Healthy Non-Smoking Adults From 17 Countries In Different Regions Of The World. , 2011, , .		0
175	Risk Stratification in the Setting of Non-ST Elevation Acute Coronary Syndromes 1999-2007. American Journal of Cardiology, 2011, 108, 617-624.	0.7	53
176	Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia, 2011, 54, 487-495.	2.9	48
177	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European Heart Journal, 2011, 32, 581-589.	1.0	199
178	The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study. Journal of Medical Economics, 2011, 14, 792-797.	1.0	6
179	Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries. PLoS ONE, 2010, 5, e14294.	1.1	70
180	Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes. Heart, 2010, 96, 1201-1206.	1,2	42

#	Article	IF	Citations
181	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. JAMA - Journal of the American Medical Association, 2010, 304, 1339-1349.	3.8	161
182	Rationale and Design of INTERSTROKE: A Global Case-Control Study of Risk Factors for Stroke. Neuroepidemiology, 2010, 35, 36-44.	1.1	76
183	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. European Heart Journal, 2010, 31, 667-675.	1.0	63
184	Initial Clinical Results Using Intracardiac Electrogram Monitoring to Detect and Alert Patients During Coronary Plaque Rupture and Ischemia. Journal of the American College of Cardiology, 2010, 56, 1089-1098.	1.2	39
185	Can an elderly woman's heart be too strong?. American Heart Journal, 2010, 160, 849-854.	1.2	21
186	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, The, 2010, 376, 1233-1243.	6.3	725
187	Refletir a prática clÃnica: a inovação na intervenção. Revista Brasileira De Cardiologia Invasiva, 2010, 18, 247-248.	0.1	0
188	The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 319-324.	0.8	154
189	Association of Elevated Fasting Glucose With Increased Short-term and 6-Month Mortality in ST-Segment Elevation and Non–ST-Segment Elevation Acute Coronary Syndromes. Archives of Internal Medicine, 2009, 169, 402.	4.3	86
190	Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart, 2009, 95, 888-894.	1.2	68
191	Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. Haematologica, 2009, 94, 1220-1226.	1.7	55
192	The authors' reply:. Heart, 2009, 95, 1355-1356.	1.2	0
193	Education and risk for acute myocardial infarction in 52 high, middle and low-income countries: INTERHEART case-control study. Heart, 2009, 95, 2014-2022.	1.2	109
194	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. New England Journal of Medicine, 2009, 360, 2165-2175.	13.9	748
195	Cardiovascular disease in South America: current status and opportunities for prevention. Heart, 2009, 95, 1475-1482.	1.2	26
196	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. American Heart Journal, 2009, 157, 763-770.	1.2	28
197	Pulmonary artery catheterization in patients with acute coronary syndromes. American Heart Journal, 2009, 158, 170-176.	1.2	8
198	Unprotected left main revascularization in patients with acute coronary syndromes. European Heart Journal, 2009, 30, 2308-2317.	1.0	108

#	Article	IF	Citations
199	Effect of Telmisartan on Renal Outcomes. Annals of Internal Medicine, 2009, 151, 1.	2.0	163
200	Incidence and risk factors for agranulocytosis in Latin American countries—the Latin Study. European Journal of Clinical Pharmacology, 2008, 64, 921-929.	0.8	51
201	Magnitude and Prognosis Associated With Ventricular Arrhythmias in Patients Hospitalized With Acute Coronary Syndromes (from the GRACE Registry). American Journal of Cardiology, 2008, 102, 1577-1582.	0.7	31
202	Specific barriers to the conduct of randomized trials. Clinical Trials, 2008, 5, 40-48.	0.7	144
203	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. European Heart Journal, 2008, 30, 321-329.	1.0	108
204	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal, 2008, 156, 37-43.	1.2	183
205	Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE) Tj ETQq1 1	0.784314 6.3	rgBT/Overl
206	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European Heart Journal, 2008, 30, 900-907.	1.0	115
207	Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure. Circulation, 2008, 118, 1163-1171.	1.6	48
208	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation, 2008, 118, 2038-2046.	1.6	98
209	Antitrombóticos nas sÃndromes coronarianas agudas: diretrizes atuais e novas evidências. Revista Brasileira De Terapia Intensiva, 2008, 20, .	0.1	1
210	Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events. European Heart Journal, 2007, 29, 1275-1282.	1.0	167
211	Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2007, 298, 2399.	3.8	149
212	Risk Factors for Acute Myocardial Infarction in Latin America. Circulation, 2007, 115, 1067-1074.	1.6	273
213	Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification. American Heart Journal, 2007, 153, 493-499.	1.2	15
214	Interactions between heparins, glycoprotein Ilb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2007, 153, 960-969.	1.2	23
215	Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2007, 100, 1-6.	0.7	122
216	Comparison of Utilization of Statin Therapy at Hospital Discharge and Six-Month Outcomes in Patients With an Acute Coronary Syndrome and Serum Low-Density Lipoprotein ≥100 mg/dl Versus <100 mg/dl. American Journal of Cardiology, 2007, 100, 913-918.	0.7	23

#	Article	IF	CITATIONS
217	Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine, 2006, 355, 1551-1562.	13.9	684
218	Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2006, 151, 1123-1128.	1.2	78
219	Cardiovascular diseases in Latin America and the Caribbean: The present situation. Prevention and Control: the Official Journal of the World Heart Federation, 2006, 2, 149-157.	0.3	8
220	Estatinas na sepse: nova arma terap \tilde{A}^a utica no arsenal da medicina intensiva?. Revista Brasileira De Terapia Intensiva, 2006, 18, 402-406.	0.1	0
221	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ: British Medical Journal, 2006, 333, 1091.	2.4	1,236
222	Platelets and atherothrombosis: An essential role for inflammation in vascular disease $\hat{a} \in A$ review. International Journal of Angiology, 2005, 14, 211-217.	0.2	5
223	How strong is the evidence for the use of perioperative \hat{l}^2 blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2005, 331, 313-321.	2.4	366
224	Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study. BMJ: British Medical Journal, 2005, 330, 441.	2.4	104
225	Impact of age on management and outcome of acute coronary syndrome: Observations from the global registry of acute coronary events (GRACE). American Heart Journal, 2005, 149, 67-73.	1.2	514
226	Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. JAMA - Journal of the American Medical Association, 2004, 292, 45-54.	3.8	702
227	A Validated Prediction Model for All Forms of Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2004, 291, 2727.	3.8	1,344
228	Brazilian Sepsis Epidemiological Study (BASES study). Critical Care, 2004, 8, R251.	2.5	289
229	Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction11Guest Editor for this manuscript was Peter B. Berger, MD, Mayo Clinic, Rochester, Minn American Heart Journal, 2004, 147, 253-259.	1.2	74
230	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. American Journal of Medicine, 2004, 117, 73-81.	0.6	198
231	Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, The, 2004, 364, 937-952.	6.3	9,716
232	Stenting and glycoprotein Ilb/Illa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE). Catheterization and Cardiovascular Interventions, 2003, 60, 360-367.	0.7	10
233	Risk factors for myocardial infarction in Brazil. American Heart Journal, 2003, 146, 331-338.	1.2	107
234	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2003, 146, 999-1006.	1.2	104

#	Article	IF	CITATIONS
235	Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 2003, 107, 1284-1290.	1.6	207
236	Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. Archives of Internal Medicine, 2003, 163, 2345.	4.3	1,856
237	Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet, The, 2002, 359, 373-377.	6.3	496
238	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). American Journal of Cardiology, 2002, 89, 791-796.	0.7	271
239	 Diretrizes do Grupo de Estudos em Cardiogeriatria da Sociedade Brasileira de Cardiologia . Arquivos Brasileiros De Cardiologia, 2002, 79, .	0.3	7
240	The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina. American Journal of Cardiology, 1999, 84, 7-12.	0.7	51
241	Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet, The, 1998, 352, 507-514.	6.3	340
242	O impacto da espiritualidade na saúde fÃsica. Revista De Psiquiatria Clinica, 0, 34, 88-94.	0.6	60
243	IV Diretrizes Brasileiras de Hipertensão Arterial Grupos de trabalho. Arquivos Brasileiros De Cardiologia, 0, 82, .	0.3	2
244	III Diretriz sobre tratamento do infarto agudo do miocárdio. Arquivos Brasileiros De Cardiologia, 0, 83, 1-86.	0.3	24